文献速递前列腺癌

局部消融放疗能否使去势抵抗性前列腺癌逆转至更早期阶段?

Can Local Ablative Radiotherapy Revert Castration-resistant Prostate Cancer to an Earlier Stage of Disease?
PubMed 文献 · Eur Urol · 2018-12-18

这项回顾性探索性研究纳入15例寡转移性去势抵抗性前列腺癌(CRPC)患者,经68Ga-PSMA-PET引导行局部消融放疗(aRT),雄激素剥夺治疗不变。11例(73%)出现PSA应答,平均至PSA进展时间17.9个月,而按PSADT估算未行aRT为2.9个月(p<0.001)。

要点

  • PSMA-PET引导aRT在部分寡转移CRPC中可诱导PSA应答。
  • 11/15例(73%)出现PSA应答,6例>12个月无PSA进展。
  • 平均至PSA进展17.9个月,显著长于PSADT估算的2.9个月。

核心结论

  • 在部分CRPC患者中,对PET阳性主导转移灶行局部消融放疗可产生PSA应答。

研究设计与样本

  • 回顾性、探索性研究,从前瞻性机构数据库筛选2013至2016年治疗的15例寡转移性CRPC患者。
  • 经多学科讨论后行PSMA-PET引导的局部消融放疗,采用两种不同方案,雄激素剥夺治疗保持不变。

主要发现

  • 11例(73%)观察到PSA应答。
  • 至PSA进展或末次随访的平均时间为17.9个月,而按PSADT估算未行aRT为2.9个月(p<0.001)。
  • 6例患者在>12个月内未检测到PSA进展。

关键数值与推荐

  • 15例患者转移灶数量≤3个。
  • PSA应答11例(73%)。
  • 平均至PSA进展17.9个月 vs 按PSADT估算2.9个月(p<0.001)。

临床怎么用

  • 对雄激素剥夺治疗期间PSA升高的精选患者,可用PSMA-PET识别寡转移灶并考虑局部消融放疗。
  • 该策略可能延长PSA进展时间,但需前瞻性试验验证。

局限性

  • 回顾性、探索性设计,样本量仅15例。
  • 单中心机构数据库来源,aRT方案不一致。
  • 无对照组,对照为基于PSADT的个体化估算。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In prostate cancer, disease progression after primary treatment and subsequent androgen deprivation therapy is common. Intensification of systemic treatment is the standard of care. Recently, 68Ga prostate-specific membrane antigen positron emission tomography (PSMA-PET) imaging was introduced to identify oligometastatic prostate cancer patients. In this retrospective, exploratory study, we report on the efficacy of PSMA-PET-guided local ablative radiotherapy (aRT) in 15 oligometastatic castration-resistant prostate cancer (CRPC) patients, selected from our prospective institutional database and treated between 2013 and 2016. After multidisciplinary discussion, aRT was delivered with two different schedules. Androgen deprivation therapy remained unchanged. Prostate-specific antigen (PSA) response and time to PSA progression were analysed. For comparison, individual time to PSA progression without aRT was estimated by individual PSA doubling time (PSADT). PSA response was observed in 11 patients (73%). Mean time to PSA progression or last follow-up was 17.9mo, as opposed to 2.9mo estimated from the PSADT without aRT (p<0.001). A relevant subset of CRPC patients had a PSA response with aRT to PET-positive lead metastases. A prospective trial is in preparation. PATIENT SUMMARY: In selected patients with prostate-specific antigen (PSA) increase during androgen deprivation, metastases were detected with prostate-specific membrane antigen positron emission tomography imaging. Fifteen patients with three or fewer metastases were treated with high-dose radiotherapy. Subsequently, PSA values dropped in 11 patients and in six patients no PSA progression was detected for >12mo.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Lohaus F, Zöphel K, Löck S, et al. Can Local Ablative Radiotherapy Revert Castration-resistant Prostate Cancer to an Earlier Stage of Disease? Eur Urol. 2018. PMID: 30578119. doi:10.1016/j.eururo.2018.11.050

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。